Product Name

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
  • Name

    PENTAZOCINE

  • EINECS 206-634-6
  • CAS No. 359-83-1
  • Article Data10
  • CAS DataBase
  • Density 1.036g/cm3
  • Solubility
  • Melting Point 145.4-147.20ºC
  • Formula C19H27 N O
  • Boiling Point 403.5°C at 760 mmHg
  • Molecular Weight 285.429
  • Flash Point 180.8°C
  • Transport Information
  • Appearance Crystalline Solid
  • Safety Poison by ingestion, subcutaneous, intramuscular, intraperitoneal, and intravenous routes. Experimental reproductive effects. Human systemic effects by intramuscular and intravenous routes: wakefulness, euphoria, hallucinations or distorted perceptions, tremors, convulsions, excitement, motor activity changes, muscle weakness, analgesia, withdrawal, parasympathomimetic effects, nausea or vomiting, and dermititis. Can cause drug dependency and other central nervous system effects. An analgesic. When heated to decomposition it emits toxic fumes of NOx. See also ALLYL COMPOUNDS.
  • Risk Codes 22
  • Molecular Structure Molecular Structure of 359-83-1 (PENTAZOCINE)
  • Hazard Symbols HarmfulXn
  • Synonyms 2,6-Methano-3-benzazocin-8-ol,1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2R,6R,11R)-rel-(9CI); 2,6-Methano-3-benzazocin-8-ol,1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2a,6a,11R*)- (8CI); (?à)-Pentazocine;1,2,3,4,5,6-Hexahydro-3-(3-methyl-2-butenyl)-6,11-dimethyl-8-hydroxy-2,6-methano-3-benzazocine;1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol;2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan;2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol;3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocine;Fortalgesic; Fortalin; Fortral; Fortwin; II-C 2; Lexir; NIH 7958; Peltazon;Pentagin; Pentazocin; Pentazocine; Sosegon; Soseton; Sosigon; Talwin; Win20228; cis-(?à)-Pentazocine;dl-Pentazocine
  • PSA 23.47000
  • LogP 3.82050

2-(3,3-Dimethylallyl)cyclazocine Chemical Properties

Product Name: 2-(3,3-Dimethylallyl)cyclazocine
The MF of 2-(3,3-Dimethylallyl)cyclazocine (CAS NO.359-83-1) is C19H27NO.
                        
The MW of 2-(3,3-Dimethylallyl)cyclazocine (CAS NO.359-83-1) is 285.42.
Synonyms of 2-(3,3-Dimethylallyl)cyclazocine (CAS NO.359-83-1): (1R,9R,13R)-1,13-Dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0~2,7~]trideca-2,4,6-trien-4-ol ; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan ; Fortalin
Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Agonists;Opioids;Pharmacologicals
Apperance: Crystalline Solid
Index of Refraction: 1.553 
EINECS: 206-634-6
Density: 1.036 g/ml
Flash Point: 180.8 °C 
Boiling Point: 403.5 °C
Melting Point: 145-147 °C

2-(3,3-Dimethylallyl)cyclazocine Uses

 2-(3,3-Dimethylallyl)cyclazocine (CAS NO.359-83-1) is used as mixed opioid agonist-antagonist,controlled substance and analgesic (narcotic).

2-(3,3-Dimethylallyl)cyclazocine Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
human LDLo oral 18mg/kg (18mg/kg) LUNGS, THORAX, OR RESPIRATION: BRONCHIECTASIS Clinical Toxicology. Vol. 10, Pg. 327, 1977.
human TDLo intramuscular 571ug/kg (0.571mg/kg) BEHAVIORAL: EUPHORIA

GASTROINTESTINAL: NAUSEA OR VOMITING

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"		 Journal of Pharmacology and Experimental Therapeutics. Vol. 143, Pg. 149, 1964.
human TDLo intravenous 300mg/kg/D (300mg/kg) BEHAVIORAL: ANALGESIA

BEHAVIORAL: WITHDRAWAL		 British Medical Journal. Vol. 2, Pg. 21, 1978.
mammal (species unspecified) LD50 intraperitoneal 140mg/kg (140mg/kg)   United States Patent Document. Vol. #4205173,
man TDLo intramuscular 83mg/kg/4Y-I (83mg/kg) MUSCULOSKELETAL: JOINTS Archives of Internal Medicine. Vol. 143, Pg. 2203, 1983.
man TDLo intravenous 3mg/kg/2D-I (3mg/kg) BEHAVIORAL: WAKEFULNESS

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"

BEHAVIORAL: EXCITEMENT		 Journal of Pharmacology and Experimental Therapeutics. Vol. 143, Pg. 149, 1964.
mouse LD50 intramuscular 98mg/kg (98mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"		 Archives Internationales de Pharmacodynamie et de Therapie. Vol. 190, Pg. 124, 1971.
mouse LD50 intraperitoneal 85mg/kg (85mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: ANALGESIA

BEHAVIORAL: ATAXIA		 Chemical and Pharmaceutical Bulletin. Vol. 24, Pg. 2912, 1976.
mouse LD50 intravenous 19800ug/kg (19.8mg/kg)   Drugs in Japan Vol. 6, Pg. 777, 1982.
mouse LD50 oral 305mg/kg (305mg/kg)   Acta Medicia Okayama. Vol. 35, Pg. 179, 1981.
mouse LD50 subcutaneous 140mg/kg (140mg/kg)   Acta Medicia Okayama. Vol. 35, Pg. 179, 1981.
rat LD50 intramuscular 175mg/kg (175mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"		 Archives Internationales de Pharmacodynamie et de Therapie. Vol. 190, Pg. 124, 1971.
rat LD50 intravenous 21mg/kg (21mg/kg)   "Synthetic Analgesics," Oxford, Pergamon Press, 1966Vol. 2, Pg. 174, 1966.
rat LD50 oral 1110mg/kg (1110mg/kg) AUTONOMIC NERVOUS SYSTEM: OTHER (DIRECT) PARASYMPATHOMIMETIC

BEHAVIORAL: TREMOR

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD		 Kiso to Rinsho. Clinical Report. Vol. 4, Pg. 2145, 1970.
rat LD50 subcutaneous 165mg/kg (165mg/kg)   Acta Medicia Okayama. Vol. 35, Pg. 179, 1981.
rat LD50 unreported 280mg/kg (280mg/kg) BEHAVIORAL: ANALGESIA Pharmacological Research Communications. Vol. 5, Pg. 175, 1973.
women TDLo intramuscular 1400mg/kg/3Y (1400mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: MUSCLE WEAKNESS

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"		 JAMA, Journal of the American Medical Association. Vol. 231, Pg. 271, 1975.

2-(3,3-Dimethylallyl)cyclazocine Safety Profile

Poison by ingestion, subcutaneous, intramuscular, intraperitoneal, and intravenous routes. Experimental reproductive effects. Human systemic effects by intramuscular and intravenous routes: wakefulness, euphoria, hallucinations or distorted perceptions, tremors, convulsions, excitement, motor activity changes, muscle weakness, analgesia, withdrawal, parasympathomimetic effects, nausea or vomiting, and dermititis. Can cause drug dependency and other central nervous system effects. An analgesic. When heated to decomposition it emits toxic fumes of NOx. See also ALLYL COMPOUNDS.Safety information of 2-(3,3-Dimethylallyl)cyclazocine (CAS NO.359-83-1):
Hazard Codes  HarmfulXn
Risk Statements  
R22:Harmful if swallowed. 
RTECS  PB8750000

Related Products

Hot Products

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View